Cargando…

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma

OBJECTIVE: Endocrine therapy is frequently administered in patients with hormone dependent (HR+) metastatic endometrial cancer. ESR1 mutations have emerged as a key mechanism of aromatase inhibitor (AI) resistance in HR + metastatic breast cancer and can be monitored using circulating tumor DNA (ctD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drouyer, Aurélien, Beaussire, Ludivine, Jorda, Pauline, Leheurteur, Marianne, Guillemet, Cécile, Berghian, Anca, Georgescu, Dragos, Di Fiore, Frédéric, Perdrix, Anne, Clatot, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625264/ https://www.ncbi.nlm.nih.gov/pubmed/37924026 http://dx.doi.org/10.1186/s12885-023-11559-x

Ejemplares similares

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2018)

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
por: Clatot, Florian, et al.
Publicado: (2016)

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2021)

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
por: Clatot, Florian, et al.
Publicado: (2020)

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy
por: Lambertini, Matteo, et al.
Publicado: (2019)

ESR1 mutations in breast cancer
por: Clatot, Florian, et al.
Publicado: (2017)

ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment
por: Dessources, Kimberly, et al.
Publicado: (2022)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

The nature of the ESR signal in lyophilized tissue and its relevance to malignancy.
por: Dodd, N. J., et al.
Publicado: (1984)

Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma
por: Fontanilles, Maxime, et al.
Publicado: (2020)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival
por: Einarsdóttir, K, et al.
Publicado: (2009)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation
por: Barua, David, et al.
Publicado: (2020)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
por: Li, Li, et al.
Publicado: (2020)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
por: Betz, Margaux, et al.
Publicado: (2023)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

Impact of EGFR(A289T/V) mutation on relapse pattern in glioblastoma
por: Noeuveglise, A., et al.
Publicado: (2022)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

ESR1 and ESR2 genotypes and the age at menarche in idiopathic scoliosis
por: Janusz, Piotr, et al.
Publicado: (2014)

Stochastic Cooling at the ESR
por: Beckert, Karl, et al.
Publicado: (2000)

Stochastic cooling at the ESR
por: Beckert, K, et al.
Publicado: (1999)

Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
por: Fontanilles, Maxime, et al.
Publicado: (2020)

Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer
por: Anderson, Richard A., et al.
Publicado: (2022)

The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
por: Du, Yangfan, et al.
Publicado: (2018)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Vitamin D interacts with Esr1 and Igf1 to regulate molecular pathways relevant to Alzheimer’s disease
por: Landel, Véréna, et al.
Publicado: (2016)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
por: Berger, Frédérique, et al.
Publicado: (2022)

Darmstadt: SIS/ESR inauguration
Publicado: (1990)

ESR signals of lyophilized tissue.
por: Dodd, N. J., et al.
Publicado: (1980)

Clinical audit—ESR perspective
Publicado: (2010)

ESR position paper on ultrasound
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fi85c770hcs4jt7060he663rld